Janssen Pharmaceuticals – lupus research
The global biopharmaceutical company Janssen Research & Development, LLC (Janssen) has joined the Lupus Low Disease Activity State (LLDAS) Study, an international, multi-centre study investigating whether LLDAS is associated with improved outcomes in patients with Systemic Lupus Erythematosus (SLE), which is based at the School of Clinical Sciences at Monash Health (SCS).
Janssen has joined existing collaborators, UCB Biopharma SPRL and GlaxoSmithKline (GSK) to fund research led by Professor Eric Morand, Head of SCS and Head of Rheumatology at Monash Health, to develop and validate treatment targets in lupus. The target is expected to be used in clinical trials and in clinical practice to drive better outcomes for patients. In addition, the study is creating one of the largest data sets on lupus patients ever collected.